Loading...

Genta Incorporated is a biopharmaceutical company focused on the identification, development and commercialization of drugs for the treatment of people with cancer. Genta has built a broad portfolio of proprietary products in various stages of clinical development. The Company’s drugs include Ganite® (gallium nitrate injection), tesetaxel, and oral gallium. Genta is committed to developing innovative products to better the lives of people with cancer.  Learn More

Loading...
home-callout-1-top
Leadership in Cancer Drug Development

Genta's team has extensive drug development and commercialization experience.

Read More
Loading...
home-callout-2
Oncology Focused Pipeline

Tesetaxel is a novel oral Targeted Tubulin Inhibitor and is the leading oral taxane in clinical development

Read More

genta-logo-sm

  • May 14, 2012
    Genta Incorporated Reports First Quarter 2012 Financial Results
    Read More
  • May 8, 2012
    Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer
    Read More
  • April 24, 2012
    Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to its Board of Directors
    Read More
  • April 4, 2012
    Tesetaxel Clinical Data in Gastric Cancer and Breast Cancer to be Featured at ASCO Annual Meeting
    Read More
  • March 29, 2012
    Genta Completes Financing of Up to $12.0 Million
    Read More
  •  2012 BIO International Convention/BIO Business Forum 

    2012-06-18
    Boston, MA
  •  ASCO Annual Meeting

    2012-06-01
    Chicago, IL
  •  Q’1 2012 Financial Results

    2012-05-14
    Berkeley Heights, NJ
  •  AACR Annual Meeting

    2012-03-31
    Chicago, IL
  •  Q'4 2011 Highlights and Financials Results

    2012-03-28
    Berkeley Heights, NJ
  •  14th Annual BIO CEO & Investor Conference

    2012-02-13
    New York, NY
  •  ASCO Gastrointestinal Cancers Symposium

    2012-01-19
    San Francisco, CA